Recent Interviews

Ryan Jackson, CEO, Newlox Gold Ventures Corp.

Ryan Jackson
CEO | Newlox Gold Ventures Corp.
60 Laurie Crescent, V7S 1B7 West Vancouver (CAN)

+1 778 738 0546

Newlox CEO Ryan Jackson on building a green gold producer with a rapid growth trajectory

Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company

Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential

29. July 2020 | 07:29 CET

BioNTech, Eastman Kodak, EXMceuticals - investors have the chance to profit

  • Health
Photo credits:

The importance of health has not been as clear for a long time as it was in 2020. Detached from the discussion about the specifics of COVID-19 on mortality compared to other viruses, the need for protection is great and helplessness without a medical response is harmful to the common good. For this reason, experts around the globe are working to find active ingredients and reduce dependence on China for care. Investors have the opportunity to profit from this development.

time to read: 2 minutes by Mario Hose



Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author

Vaccine for COVID-19 under test

BioNTech describes itself as a next generation immunotherapy company that is pioneering the development of therapies for cancer and other serious diseases. Its activities focus on combining a variety of modern therapeutic platforms and bioinformatics tools to rapidly advance the development of novel biopharmaceuticals. Based on its extensive expertise in the development of mRNA vaccines, BioNTech is also working with collaboration partners to develop various mRNA vaccine candidates for a number of infectious diseases.

Together with Pfizer, BioNTech is working on the development of a vaccine for COVID-19, and the company recently announced that a vaccine candidate can participate in a Phase 2/3 study. The selection of candidates for this study has already been made based on data from the Phase 1/2 study in Germany and the USA. Up to 30,000 people aged between 18 and 85 years will participate in the study in approximately 120 study centers worldwide. If successful, up to 100 million vaccine doses will be made available by the end of the year and over 1.3 billion doses by the end of 2021.

Expanding independence from China

The capital market-oriented US President Donald Trump has announced that Eastman Kodak will receive a state loan of USD 765 million under the Defense Production Act. The company was formerly active in the photographic equipment sector and is known under the Kodak brand name. However, Kodak was not prepared for the success of digital photography and quickly fell into disarray. Management now plans to use the U.S. government's money to produce important ingredients for medicines.

In connection with the Corona Pandemic, it became clear how dependent the world community is on Chinese producers. Restrictions in supply chains led to bottlenecks in the supply of equipment to the population. In addition to Kodak, 3M for the production of protective masks and General Motors for the production of respirators were already able to benefit from the 1950 law in connection with the Korean War.

CEO increases stake in company

EXMceuticals is a young life science company focused on the wellness and medical applications of cannabinoids and terpenes. The subsidiary EXM Portugal has licenses and permits for cannabis research for its existing laboratory and pilot refinery in Lisbon. The company has already completed research projects with Universidade Nova de Lisboa and Universidade Lusofona and has applied for P2020 research grants.

In addition to the scientific mission, EXMceuticals claims that it is planning and building a much larger and additional plant in Portugal, which will be operated as an EU GMP refinery. Once this industrial refinery is completed and licensed, it will be used by the company as a base for the distribution of cannabis ingredients in the EU and North America on a commercial basis. The company's activities focus on the production of high-quality cannabis and hemp ingredients for the pharmaceutical, therapeutic, nutraceutical and cosmetic industries. The company intends to sell the produced ingredients to international medical markets. As part of a financing, CEO Jonathan Summers converted previous loans to EXMceuticals into shares of the company and now holds more than 16% of the voting rights.


Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author

Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.

Related comments:

27. October 2020 | 10:17 CET | by André Will-Laudien

Pfizer, GlaxoSmithKline, EXMceuticals - Research in competition

  • Health

By the end of 2020, the drug market is expected to more than double to USD 1.3 trillion, with the E7 countries - Brazil, China, India, Indonesia, Mexico, Russia and Turkey - accounting for about one-fifth of global drug sales. Also, the incidence of chronic diseases in developing countries will increasingly resemble that in industrialized countries. The evidence is abundant that the pharmaceutical industry business model is both economically unsustainable and operationally lethargic to produce the types of innovative treatments demanded by global markets. The industry must fundamentally change the way it operates to take full advantage of future growth opportunities. PwC's management consultants expect the industry to shift its focus from treatment to prevention. The traditional blockbuster sales model will disappear, and sophisticated direct sales channels will diminish the role of wholesalers. Let's take a closer look!


29. September 2020 | 10:51 CET | by Mario Hose

BioNTech, Bayer, Valeo Pharma: Share price jump ahead of quarterly results

  • Health

Investors' expectations of developments can drive the share price. When it comes to solving a problem or creating needs, the interest of the capital market is particularly high. Things get exciting for investors when the business model offers the possibilities of scalability. Attractive investment opportunities can be created in the fields of health and medicine, which offer extraordinary return opportunities.


08. June 2020 | 11:30 CET | by Mario Hose

Aurora, Bayer, XPhyto - scalable growth markets with potential

  • Health

Health is the most precious good in the life of a human being. The preservation and improvement of the quality of life is a large business area. Investors around the globe have the opportunity to participate in many different areas of research and development of products and therapies. The development of new markets and preparations usually requires a lot of risk capital before the fruits can be harvested. At the latest when a scalable solution has been found to improve people's lives, then the value of the company increases.